RXST (RxSight) Marketable Securities: $195.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RXST RxSight Inc RXST
65 GF Score
Price $6.38
GF Value $26.77
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is RxSight Marketable Securities?

RxSight RXST -0.31% 65 Marketable Securities is $195.4 Mil as of Jun. 2026. GuruFocus rates RXST with a GF Score™ of 65/100 and a GF Value™ of $26.77 (Possible Value Trap). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. RxSight's Marketable Securities for the quarter that ended in Jun. 2026 was $195.4 Mil.

RxSight's annual Marketable Securities increased from Dec. 2023 ($117.5 Mil) to Dec. 2024 ($220.5 Mil) but then declined from Dec. 2024 ($220.5 Mil) to Dec. 2025 ($208.2 Mil).

RxSight  (NAS:RXST) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

RxSight Marketable Securities Related Terms

RxSight Marketable Securities Historical Data

* Premium members only.

The historical data trend for RxSight's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RxSight Marketable Securities Chart

RxSight Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 134.97 93.97 117.49 220.52 208.18

RxSight Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187.14 197.88 208.18 200.31 195.45
RXST
65GF Score
RxSight Inc RXST
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RxSight Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $195.4 Mil mean?
RxSight (RXST) has a Marketable Securities of $195.4 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on RxSight and its competitors.
Is RxSight's Marketable Securities too high?
RxSight's current Marketable Securities is $195.4 Mil. Overall, RxSight has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RxSight's Marketable Securities compare to INFU and SENS?
RxSight's Marketable Securities of $195.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on RxSight and its competitors. RxSight's current Marketable Securities is $195.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RxSight stock overvalued right now?
Based on GuruFocus' analysis, RxSight (RXST) is currently considered Possible Value Trap. The stock's GF Value™ is $26.77, compared to a current price of $6.38 — trading 76.2% below its estimated fair value. The current Marketable Securities is $195.4 Mil. RxSight's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For RxSight (RXST), the current Marketable Securities is $195.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RxSight (RXST) Overvalued in 2026?

Based on GuruFocus' analysis, RxSight stock appears to be undervalued. The current stock price of $6.38 is trading 76.2% below its estimated GF Value™ of $26.77. GuruFocus considers RxSight to be Possible Value Trap.

Key valuation signals for RXST:

  • Marketable Securities: $195.4 Mil
  • GF Value™: $26.77 vs. price of $6.38 (76.2% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the RXST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RxSight Business Description

Address 100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
65GF Score

Get the complete analysis for RXST

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.38
Price
$26.77
GF Value